Cyclosporine A, Alpha-Interferon and Interleukin-2 Following Chemotherapy with BCNU, DTIC, Cisplatin, and Tamoxifen: A Phase II Study in Advanced Melanoma

References

• Wittes, R E.; Wittes, J T.; Golbey, R B. Combination chemotherapy in metastatic malignant melanoma. Cancer 1978, 41, 415–421. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Luikart, S D.; Kennealey, G T.; Kirkwood, J M. Randomized phase II trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J. Clin. Oncol. 1984, 2, 164–168. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Del Prete, S A.; Maurer, L H.; O'Donnell, J.; Forcier, R J.; LeMarbre, P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 1984, 68, 1403–1405. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• McClay, E F.; Mastrangelo, M J.; Bellet, R E.; Berd, D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat. Rep. 1987, 71, 465–469. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• McClay, E F.; Mastrangelo, M J.; Sprandio, J D.; Bellet, R E.; Berd, D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989, 63, 1292–1295. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rusthoven, J J.; Quirt, I C.; Iscor, N D.; McCulloch, P B.; James, K W.; Reinhard, R C.; Lohmann, J J.; Burdette-Radoux, S.; Bodurtha, A J.; Silver, H K.B.; Verma, S.; Armitage, G R.; Zee, B.; Bennett, K. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J. Clin. Oncol. 1996, 14, 2083–2090. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• O'Day, S J.; Gammon, G.; Boasberg, P D.; Martin, M A.; Kristedja, T S.; Guo, M.; Stern, S.; Edwards, S.; Fournier, P.; Weisburg, M.; Cannon, M.; Fawzy, N W.; Johnson, T D.; Essner, R.; Foshag, L J.; Morton, D L. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol. 1999, 17, 2752, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Falkson, C I.; Ibrahim, J.; Kirkwood, J M.; Coates, A S.; Atkins, M B.; Blum, R H. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1998, 16, 1743, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Feun, L G.; Savaraj, N.; Moffatt, F.; Robinson, D.; Liebmann, A.; Hurley, J.; Raub, W A., Jr.; Richman, S P. Phase II trial of recombinant alpha-interferon with BCNU, cisplatin, DTIC, and tamoxifen in advanced, malignant melanoma. Melanoma Res. 1995, 5, 273–276. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Legha, S S.; Ring, S.; Eton, O.; Bedikian, A.; Buzaid, A C.; Plager, C.; Papadapoulos, N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastdine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 1998, 16, 1752, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Keilholz, U.; Goey, S H.; Punt, C J.; Proebstle, T M.; Salzmann, R.; Scheibenbogen, C.; Schadendorf, D.; Lienard, D.; Enk, A.; Dummer, R.; Hantich, B.; Geueke, A.-M.; Eggermont, A M.M. Interferon alfa-2a and interleukin 2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research andTreatment of Cancer Melanoma Cooperative Group. J. Clin. Oncol. 1997, 15, 2579–2588. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rosenberg, S A.; Yang, J C.; Schwartzentruber, D J.; Hwu, P.; Marcincola, F M.; Topalian, S L.; Seipp, C A.; Einhorn, J H.; White, D E.; Steinberg, S M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin 2 and interferon alfa-2a. J. Clin. Oncol. 1999, 17, 968, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Eton, O.; Legha, S S.; Bedikian, A Y.; Lee, J J.; Buzaid, A C.; Hodges, C.; Ring, S E.; Papadopoulos, N E.; Plager, C.; East, M J.; Zhan, F.; Benjamin, R S. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase II randomized trial. J. Clin. Oncol. 2002, 20, 2045–2052. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hess, A D.; Hormtz; Beschorner, W E.; Santos, G W. Development of graft versus host disease-like syndrome in cyclosporin-treated rats after syngeneic bone marrow transplantation. J. Exp. Med. 1985, 161, 718–730. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Perry, L L.; Dorf, M e.; Benacerraf, B.; Greene, M I. Regulation of immune response to tumor antigen: interference with syngeneic tumor immunity by anti-IA alloantisera. Proc. Natl. Acad. Sci. 1979, 76, 920–924. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Charak, B S.; Agah, R.; Mazumder, A. Synergism of interleukin-2 and cyclosporine A in induction of a graft versus tumor effect without graft versus host disease after syngeneic bone marrow transplantation. Blood 1992, 79, 179–184.
   Google Scholar
• Kroczek, R A.; Black, C D.; Barbet, J.; Shevach, E M. Mechanism of action of cyclosporin A in vivo: cyclosporin A fails to inhibit T lymphocyte activation in response to alloantigens. J. Immunol. 1987, 139, 3597–3603. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Thomson, A w.; Moon, D K.; Inoue, Y.; Geczy, C L.; Nelson, D S. Modification of delayed type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea pigs. Immunology 1983, 48, 301–308. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Noble, R L.; Steinmuller, D. Blocking of interleukin-2 production but not the tissue destruction induced by cytotoxic T cells by cyclosporine. Transplantation 1989, 47, 322–326. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jones, R J.; Vogelsang, S B.; Hess, A D.; Farmer, E R.; Mann, R B.; Gellar, R B.; Piantadosi, S.; Santos, G W. Induction of graft versus host disease after autologous bone marrow transplantation. Lancet 1989, 2, 754–756. [CROSSREF]
   Google Scholar
• Rosenberg, S.; White, D. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. 1996, 19, 81–84. [CSA]
   PubMed Web of Science ®Google Scholar
• Atkins, M B.; Lee, S.; Flaherty, L E.; Sosman, J A.; Sondak, V K.; Kirkwood, J M. A prospective randomized phase III trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc. Am. Soc. Clin. Oncol. 2003, 22, 708
   Google Scholar
• Hu, H.-M.; Poehlein, C H.; Urba, W J.; Fox, B A. Development of antitumor immune responses in reconstituted lymphopenic hosts. Can. Res. 2002, 62, 3914–3919.
   PubMed Web of Science ®Google Scholar
• Dudley, M E.; Wunderlich, J R.; Robbins, P F.; Yang, J C.; Hwu, P.; Schwartzentruber, D J.; Toopalian, S L.; Sherry, R.; Restifo, N P.; Hubicki, A M.; Robinson, M R.; Raffeld, M.; Duray, P.; Seipp, C A.; Rogers-Freezer, L.; Morton, K E.; Mavroukakis, S A.; White, D E.; Rosenberg, S A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298, 850–854. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar